

Immunotherapy for the Treatment of Skin Cancers

Katy K. Tsai, MD Assistant Clinical Professor

Melanoma & Skin Cancer Program

University of California, San Francisco









Society for Immunotherapy of Cancer




- I disclose institutional research support from Regeneron, Oncosec.
- I will be discussing non-FDA approved indications during my presentation.





- Skin cancer is the most common type of cancer
- Three most common types of skin cancers:
 - Basal cell carcinoma
 - Squamous cell carcinoma
 - Melanoma
- Melanoma was one of the foundational disease states for testing immunotherapies







Approved cytokines in melanoma

Drug	Indication	Dose
High-dose interferon alfa-2b	Adjuvant – high risk for systemic recurrence	Induction: 20m IU/m ² IV 5x/wk for 4 wks Maintenance: 10m IU/m ² s.c. 3x/wk for 48 wks
Interleukin-2 (Aldesleukin)	Stage IV	600k IU/kg/dose Q8hr, up to 14 doses; 9 days of rest; can repeat up to 28 doses per course
Pegylated Interferon alfa-2b (Sylatron)	Adjuvant – microscopic or gross nodal involvement	6 mcg/kg/wk s.c. for 8 doses, then 3 mcg/kg/wk s.c. for up to 5 years





Approved checkpoint inhibitors in melanoma


Drug	Approved	Indication	Dose
	2011	Unresectable/Metastatic melanoma: newly diagnosed or after progression	3 mg/kg Q3W for 4 doses
Ipilimumab	2015	Adjuvant therapy in stage III melanoma after complete resection	10 mg/kg Q3W for 4 doses, then 10 mg/kg Q12W for 3 years
	2017	Unresectable/Metastatic melanoma: newly diagnosed or after progression, all patients ≥ 12 yr	3 mg/kg Q3W for 4 doses





Adjuvant Ipilimumab in High-Risk Stage III Melanoma

- EORTC 18071 phase III trial
 - NCT00636168
 - Adjuvant ipilimumab vs placebo
 - Ipilimumab 10mg/kg Q3W for four doses, then every 12 weeks for up to 3 years






Adjuvant Ipilimumab in High-Risk Stage III Melanoma

- ECOG 1609
 - NCT01274338
 - Adjuvant interferon (IFN) vs ipilimumab 3 mg/kg (IPI 3) vs ipilimumab 10 mg/kg (IPI 10)
 - Ipilimumab Q3W for four doses, then every 12 weeks for up to 3 years
 - IPI 3 "better than IFN", IPI 10 "not better than IFN"
 - IPI3 better tolerated than IPI 10

Tarhini, ASCO Annual Meeting 2019. © 2019–2020 Society for Immunotherapy of Cancer




Years



Ipilimumab in Stage III/IV Melanoma

- Pooled OS data from 10 phase II/III trials
 - Previously treated (n = 1,257) or treatmentnaïve (n = 604)
 - Ipilimumab 3 mg/kg (n = 965) or 10 mg/kg (n = 706)







Approved checkpoint inhibitors in melanoma


Drug	Approved	Indication	Dose			
	2014	Advanced/unresectable melanoma with progression after other therapy	200 mg Q3W*			
Pembrolizumab	2015	1 st line unresectable/metastatic melanoma	200 mg Q3W*			
	2019	Adjuvant therapy of melanoma following complete resection	200 mg Q3W			
	*Original approvals were 2 mg/kg Q3W – updated to flat dosing regimen					






Adjuvant Pembrolizumab in High-Risk Stage III Melanoma

- EORTC 1325/KEYNOTE-054 phase III trial
 - NCT02362594
 - Adjuvant pembrolizumab vs placebo
 - Pembrolizumab 200mg Q3W for up to 1 year (~18 total doses)





Pembrolizumab in Stage III/IV Melanoma Phase III KEYNOTE-006 Trial





Approved checkpoint inhibitors in melanoma

Drug	Approved	Indication	Dose		
Nivolumab	2014	Unresectable/metastatic melanoma with progression after other therapy	240 mg Q2W or 480 mg Q4W*		
	2017	Adjuvant treatment of melanoma after complete resection	240 mg Q2W or 480 mg Q4W		
*Original approval was 3 mg/kg Q2W, updated to flat dosing regimen					





Adjuvant Nivolumab vs Ipilimumab in High-Risk Stage III Melanoma

- CheckMate 238 phase
 III trial
 - NCT02388906
 - Ipilimumab 10mg/kg Q3W for four doses, then every 3 months for up to 1 year
 - Nivolumab 3mg/kg Q2W for four doses, then every 3 months for up to 1 year

								Nľ	vo		IPI	
				Ev	ents/pa	tients		171	/453		221/453	
				Me	dian (9	5% CI)		30.8 (30	.8, NR)ª	24.	1 (16.6, N	IR)
				HR	(95% 0	CI)			0.66 (0	.54, 0.8	31)	
1	00 🤞	and the second s		Lo	g-rank	P value			<0	.0001		
	90 -			aMe	dian est	imate n	ot reliab	le or sta	able due	to few	patients a	at ris
	80 -	2	Z	~	700	,						
	70 -		Sund	and a second	70%		66%		63%)		
	60 -				0	0	1				A AMA	
	50 -				60%	/0	53			A		
	40 -				I I		100	/0	50%	0		
	30 -				I		1		Į.			
	20 -				1 1		÷		ł			
	10 -	— IPI										
	0 -			г						1		_
	0	3	6	9	12	15	18	21	24	27	30	33
					Mor	nths						
								M"	1.01010			




Approved checkpoint inhibitors in melanoma

Drug	Approved	Indication	Dose
Nivolumoh u Inilimumoh	2015	BRAF V600 WT unresectable/metastatic melanoma	1 mg/kg nivolumab + 3 mg/kg ipilimumab Q3W for 4 doses, then nivolumab 240 mg Q2W or 480 mg Q4W
Nivolumab + Ipilimumab	2016	BRAF V600 WT or mutant unresectable/metastatic melanoma	1 mg/kg nivolumab + 3 mg/kg ipilimumab Q3W for 4 doses, then nivolumab 240 mg Q2W or 480 mg Q4W





Combination Ipilimumab + Nivolumab in Stage III/IV Melanoma Phase III CheckMate 067 Trial




Hodi, Lancet Oncol 2018. © 2019–2020 Society for Immunotherapy of Cancer



Combination Ipilimumab + Nivolumab for Patients with Asymptomatic Brain Metastases


Variable	Intracranial (N=94)	Extracranial (N = 94)	Global (N = 94)
Best overall response — no. (%)*			
Complete response	24 (26)	7 (7)	8 (9)
Partial response	28 (30)	40 (43)	40 (43)
Stable disease for ≥ 6 mo	2 (2)	6 (6)	5 (5)
Progressive disease	31 (33)	28 (30)	33 (35)
Could not be evaluated†	9 (10)	13 (14)	8 (9)
Objective response <u></u> ;			
No. of patients	52	47	48
Percent of patients (95% CI)	55 (45–66)	50 (40–60)	51 (40-62)
Clinical benefit§			
No. of patients	54	53	53
Percent of patients (95% CI)	57 (47–68)	56 (46–67)	56 (46–67)







Importance of Tumor PD-L1 Status with Anti-PD-1 Monotherapy



Robert, NEJM 2015. © 2019–2020 Society for Immunotherapy of Cancer


mo (95% CI)

N.R.

N.R.


12.4 (9.2-N.R.)

10.2 (7.6-11.8)





The use of PD-L1 status to predict overall survival is poor with single-agent PD-1 or combined ipi/nivo...



PDL-1 (%)	≥1	< 1	<u>></u> 5	< 5	≻ 10	< 10
Ipilimumab	19%	18%	21%	17%	20%	18%
Nivolumab	54%	35%	58%	42%	58%	44%
lpi/Nivo	65%	54%	72%	56%	85%	55%


...but, PD-L1 status predicts higher response rate with combo at every PD-L1 expression cut-off



In development: Neoadjuvant immunotherapy in advanced melanoma

Trial	Regimen	Ν	pCR (%)	med RFS (mo)	med FU (mo)
Amaria Lancet Oncol 2018	Dab/Tram	21	58	19.7	18.6
Long Lancet Oncol 2019	Dab/Tram	35	49	23.0	27.0
Blank Nat Med 2018	lpi+nivo	10	33	NR	32
Amaria Nat Med 2018	Nivo Ipi+nivo	12 11	25 45	NR NR	20
Huang Nat Med 2019	Pembro	30	19	NR	18
Rozeman Lancet Oncol 2019	lpi+nivo	86	57	NR	8.3






Drug	Approved	Indication	Dose
Talimogene laherparepvec (T-Vec)	2015	Local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in recurrent melanoma after surgery	Intralesional injection: ≤4 mL at 10 ⁶ PFU/mL starting; 10 ⁸ PFU/mL subsequent

Society for Immunotherapy of Cance



Talimogene laherparepvec (T-VEC) in Stage III/IV Melanoma

- Phase III OPTiM Trial
 - Oncolytic, geneticallyengineered herpes virus
 - Intralesional T-VEC 106 pfu/mL, 108 pfu/mL 3 weeks after initial dose, then Q2W
 - Subcutaneous GM-CSF







Approved checkpoint inhibitors in other skin cancers


Drug	Approved	Indication	Dose
Avelumab	2017	Patients >12 yr with metastatic Merkel cell carcinoma	800 mg Q2W + premedication (first 4 cycles)
Pembrolizumab	2018	Adult/pediatric with recurrent advanced/metastatic Merkel cell carcinoma	Adults: 200 mg Q3W Pediatric: 2 mg/kg (up to 200 mg) Q3W
Cemiplimab-rwlc	2018	Metastatic cutaneous squamous cell carcinoma, not candidate for curative therapies	350 mg Q3W






Avelumab in 2nd-line metastatic Merkel Cell carcinoma

- 1st FDA-approved treatment for this status
- Avelumab 10 mg/kg Q2W
- ORR: 32%, CR: 9%; PR: 23%








Kaufman, Lancet Oncol 2016. © 2019–2020 Society for Immunotherapy of Cancer



Pembrolizumab in 1st-line advanced Merkel Cell Carcinoma


- KEYNOTE-017
- Pembrolizumab 2 mg/kg Q3W up to 2 years
- mPFS: 16.8 months (compared to 90 days for chemo)
- 24-month OS: 68.7%







Pembrolizumab in 1st-line advanced Merkel Cell Carcinoma





ACCC



Cemiplimab in advanced/metastatic cutaneous squamous-cell carcinoma

- Cemiplimab 3mg/kg Q2W
- 47% response rate in metastatic patients
- 60% of locally advanced had objective response








Developmental Immunotherapeutic Strategies for Melanoma


sitc



Modified from Liu, Jenkins, Sullivan. Amer J Clin Derm 2018. © 2019–2020 Society for Immunotherapy of Cancer




Developmental Immunotherapeutic Strategies for Melanoma





In development: Combined IO with BRAF targeted therapy


- Cobimetinib + vemurafenib + atezolizumab
- ORR: 71.8%
- Median duration of response: 17.4 mo



unotherapy of Cano



In development: Combined IO with BRAF targeted therapy





«Owing to the small number of patients enrolled in the ECOG PS 1 and LDH ≤1.1 × ULN strata, these strata were combined.





In development: Combined IO with Oncolytic Virus










In development: Combined IO with IL-2 (NKTR-214)

Efficacy (response rate) data from nonrandomized cohorts of urothelial bladder cancer, renal cell carcinoma, and melanoma looks promising



Response by Independent Radiology

Stage IV IO-Naïve 1L Melanoma Cohort at RP2D Best Overall

1L Melanoma (n=38 Efficacy Evaluable)	Overall Response Rate
Confirmed ORR (CR+PR)	20 (53%)
CR	9 (24%)
DCR (CR+PR+SD)	29 (76%)
PD-L1 negative (n=14)	6 (43%)
PD-L1 positive (n=19)	13 (68%)
PD-L1 unknown (n=5)	1 (20%)
LDH > ULN (n=11)	5 (45%)
Liver metastases (n=10)	5 (50%)


High level of concordance in ORR between independent central radiology (53%) and investigator-assessed 19/38 (50%).





In development: Combined IO with HDAC inhibitor

- Entinostat + pembrolizumab
- 19% ORR (1 CR, 9 PR)
- Median duration of response: 13 mo
- 9 additional patients with SD for >6 mo






- Melanoma was one of the foundational disease states for testing immunotherapies
- Avelumab and pembrolizumab are now approved for Merkel cell carcinoma, and cemiplimab is approved for cutaneous squamous cell carcinoma
- Combination immunotherapies may lead to higher response rates and more durable responses





Additional Resources









Case Studies







- A 54 yo man with stage IV melanoma, BRAF V600 WT, comes to your office as an urgent add-on. He has palpable metastases in bilateral axilla and subcutaneous disease that seems stable from baseline. He just received his second dose of ipilimumab/nivolumab last week, and is having diarrhea. He describes his diarrhea as 3-4 times daily, associated with mild cramping. He feels a mild subjective fever but denies weight loss, nausea and vomiting, and has been able to eat and drink at home without problems. What are immediate next steps?
- A. Take loperamide and call back if diarrhea not better in 48 hours
- B. Start prednisone 2 mg/kg daily
- C. Check stool studies, consider prednisone start





Case Study 1

- Stool studies for infectious etiologies are negative. Fecal calprotectin is high. Prednisone is started, 0.5mg/kg PO daily.
- The patient calls in 3 days later to report that his diarrhea has not improved. He follows instructions to increase his dose to 1 mg/kg PO daily, but the next day calls in to report that he vomited at home and feels weak. What are immediate next steps?
- A. Go to the nearest emergency room for evaluation
- **B.** Recommend increasing prednisone to 2 mg/kg, and call back tomorrow
- C. Recommend adding diphenoxylate/atropine and ondansentron, and call back tomorrow





Case Study 1

- The patient is hospitalized, and found to be hypotensive and have acute kidney injury. Due to difficulty tolerating PO, he receives methylprednisolone and the GI service is consulted to perform a flexible sigmoidoscopy. The admitting team is concerned about his clinical condition and asks you whether additional medical therapy is needed. You recommend:
- A. Mycophenolate mofetil
- B. Infliximab
- C. IVIG





Case Study 1

- The patient receives a dose of infliximab in addition to continuing methylprednisolone. He feels better over the next few days and is transitioned to oral prednisone, and sent home with outpatient follow up.
- The patient sees you in clinic regularly after discharge. At 6 weeks, he is off prednisone and feels well overall. He no longer has diarrhea, however notes that he can still feels bilateral axillary metastases. His restaging scans note stable to slightly decreased overall burden of disease. He inquires about whether he can restart ipilimumab/nivolumab.
- A. Yes, restart ipilimumab/nivolumab
- B. No, restart ipilimumab only
- C. No, restart nivolumab only





Case Study 2

- A 35 yo woman comes to see you (medical oncology) after removal of a mole which was diagnostic of melanoma. Her pathology report shows the melanoma was removed with a punch tool, and is 1.2mm thick, ulcerated, with a mitotic index 1/mm². Margins are negative but narrow. What do you recommend?
- A. Observation
- **B.** Wide local excision only
- **C.** Wide local excision and sentinel lymph node biopsy
- D. Adjuvant therapy to start as soon as possible





Case Study 2

- You refer her to surgical oncology for WLE/SLNB. She return after the surgery to review pathology with you, which shows micrometastatic involvement of 2 lymph nodes. What do you do?
- A. Send her back to the surgeon for a completion lymph node dissection
- **B.** Recommend adjuvant immunotherapy
- C. Recommend adjuvant radiation
- **D.** Order BRAF testing





Case Study 2

- BRAF results return positive for a BRAF V600E mutation. What do you recommend?
- A. Adjuvant nivolumab
- **B.** Adjuvant pembrolizumab
- C. Adjuvant dabrafenib/trametinib

